Brief: InflaRx Provides Update On Planned Phase III Study Design In Pyoderma Gangrenosum With Vilobelimab
05/01/2023 12:36
Jan 5 (Reuters) - InflaRx NV IF0G.F :
* INFLARX PROVIDES UPDATE ON PLANNED PHASE III STUDY DESIGN
IN
PYODERMA GANGRENOSUM WITH VILOBELIMAB AND STATUS OF ITS EUA
APPLICATION IN CRITICALLY ILL COVID-19 PATIENTS
* INFLARX NV - FDA REVIEW OF APPLICATION FOR EMERGENCY USE
AUTHORIZATION OF VILOBELIMAB FOR TREATMENT OF CRITICALLY ILL
COVID-19 PATIENTS ONGOING
* INFLARX NV: FDA REVIEW OF APPLICATION FOR EMERGENCY USE
AUTHORIZATION (EUA) OF VILOBELIMAB FOR TREATMENT OF CRITICALLY
ILL COVID-19 PATIENTS ONGOING
* INFLARX NV: TRIAL SIZE TO BE ADAPTED UPON INTERIM ANALYSIS
WITH
PLANNED TOTAL PATIENT NUMBER BETWEEN APPROXIMATELY 50 AND 100
PATIENTS
Source text for Eikon: ID:nGNX5yb7J1
Further company coverage: IF0G.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inflarx NV
See all newsBrief: Inflarx NV Files For Offerng Of Ordinary Shares, Size Not Disclosed - SEC Filing
Brief: InflaRx Reports Full Year 2025 Results And Highlights Key Achievements And Expected Milestones
Brief: Inflarx Announces Late-Breaker Oral Presentation On Vilobelimab Phase 3 Results In Pyoderma Gangrenosum At 2026 American Academy Of Dermatology Annual Meeting
Brief: Inflarx NV Executing 30% Workforce Reduction
Brief: Inflarx Provides Update On Phase 3 Data Analyses For Vilobelimab In Pyoderma Gangrenosum